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Abstract Cancer survivors are at risk of experiencing
adverse physical and psychosocial effects of their cancer and
its treatment. Both Hodgkin’s lymphoma (HL) and non-
Hodgkin’slymphoma(NHL)survivorsfaceproblemsthatcan
affect their health-related quality of life (HRQoL). The
authors systematically reviewed the literature on HRQoL
among HL and NHL survivors. A PubMed and PsychINFO
literature search for original articles published until May 2011
was performed. Twenty-four articles, which met the prede-
fined inclusion criteria, were subjected to a quality checklist.
HL survivors showed the most problems in (role) physical,
social and cognitive functioning, general health, fatigue and
financial problems. In addition, HL survivors treated with a
combination of therapies, with older age and female sex
reported worse HRQoL. NHL survivors showed the most
problems in physical functioning, appetite loss, vitality and
financial problems. Having had chemotherapy was negatively
associated with HRQoL, but no differences in chemotherapy
regimens were found. Furthermore, in NHL survivors not
meeting public exercise guidelines, HRQoL is low but can be
improved with more exercise. More research on the longitu-
dinalcomparisonbetweenHLandNHLsurvivorsandhealthy
controls should be performed in order to better understand the
long-term (side) effects of treatment on HRQoL and possibil-
ities to alleviate these.
Keywords Quality of life.Hodgkin’s lymphoma.Non-
Hodgkin’s lymphoma.Cancer treatment.Cancer survivors
Introduction
Treatment of cancer has improved considerably in the past
decades resulting in more (long-term) survivors. A person
diagnosed with cancer is defined a survivor from the
moment of diagnosis through the balance of his or her life
[1]. The number of cancer survivors in the United States
(US) has increased steadily and is currently estimated to be
11.1 million [2]. The number of lymphoma survivors has
relatively increased even more. On January 1, 2008, there
were approximately 167,000 Hodgkin’s lymphoma (HL)
survivors and approximately 454,000 non-Hodgkin’s lym-
phoma (NHL) survivors in the US [2]. In the Nordic
European Countries (NEC: Denmark, Faroe Islands, Fin-
land, Iceland, Norway, Sweden), there were approximately
10,500 HL survivors and approximately 31,500 NHL
survivors at the end of 2007 [3].
Although there are similarities between these subtypes of
lymphoma, the incidence and age of onset are quite different.
The annualincidenceofHLisonein35,000intheUS[2]a n d
one in 47,000 in the NEC [3], with approximately 8,500 new
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annually. Onset occurs most frequently between the ages of
20 and 35 years. Between 35 and 50 years, it occurs less
often especially in females, but from the age of 50 onward
there is again a rise in incidence with age [2]. The lifetime
prevalence of HL is one in 430 [2]. With respect to NHL, the
annual incidence is one in 5,000, with approximately 65,000
new cases in the US [2] and 73,000 new cases in the
European Union (NEC numbers are unavailable) [4]. The
disease occurs predominantly in individuals aged over
45 years and the lifetime prevalence of NHL is one in 50 [2].
Due to chemotherapy, radiotherapy and stem cell
transplantation, the survival of these patients has improved
dramatically in the seventies and eighties, but has nowa-
days levelled off. In effect, most trials focus on maintaining
the high level of cure, while reducing the long-term effects
of treatment. To date, more than 80% of patients diagnosed
with HL are expected to live free of disease for 5 years or
more after diagnosis [5]. The overall 5-year survival rate for
all types of NHL (1999–2005) is 50–60%. The statistics
vary depending on the cell type, stage of disease at
diagnosis, treatment and age of the patient [5].
As cancer survivors are living longer, they are at risk of
experiencing adverse physical and psychosocial long-term
effects of the fact that they had cancer or of their treatment
[6–9]. The long-term HL and NHL survivors, especially,
face specific problems, concerning mainly chronic medical
as well as psychosocial complications that can affect their
health-related quality of life (HRQoL). Fatigue, depression,
marital disruption and problems with infertility are fre-
quently reported concerns by these survivors, not to
mention problems with insurances and mortgages [6, 8–11].
Only recently, the focus of published papers has shifted
from improvement of survival to HRQoL. In December
2009, a review concerning HRQoL in lymphoma survivors
has been published [12]. This review described the HRQoL
of both HL and NHL survivors combined, which may
delude conclusions as differences in age of onset, treatment
and overall survival time between HL and NHL greatly
influences HRQoL. In addition, four prospective and two
cross-sectional studies, all published between 2004 and
2009, were not included in this review and especially these
prospective studies contain important information. Further-
more, and most important, the review did not provide
information about the clinical implications of its findings.
Many studies base their conclusions on statistical signifi-
cance, but clinical significance should also be studied for
the representation of clinically important differences to
patients. Our review will therefore distinguish itself by a
separate discussion of both types of lymphoma, a more
complete and updated overview of studies, and by
providing information about clinical significance of the
findings. The aim of this systematic review was (1) to
evaluate the quality of the included studies, (2) to identify
the HRQoL domains and symptoms that are clinically
relevant affected in HL and NHL survivors, (3) to evaluate
the relation between treatment and HRQoL and (4) to
evaluate potential differences in socio-demographic and
clinical characteristics.
Methods
Search strategy
The electronic databases of PubMed and PsychINFO were
searched to find all articles up to May 2011 using the terms
‘Hodgkin’s’ and ‘non-Hodgkin’sl y m p h o m a ’ in combination
with survivors, long-term, (health-related) quality of life, and
HRQoL. The reference lists of all publications were checked
to retrieve additional publications.
Selection criteria
Studies in English on HRQoL in HL and NHL adult
survivors were included if they used a multidimensional
HRQoL questionnaire. Studies that merely focused on one-
dimensional aspects of HRQoL such as fatigue, anxiety or
depression were excluded from this review because this is
not consistent with the multidimensional concept of
HRQoL (i.e. the existential influence of disease on
physical, emotional and social functioning). Also, studies
that involved a variety of tumours including HL or NHL,
focused on adult survivors of childhood cancer, and studies
not published in peer-reviewed journals were excluded.
Furthermore, the focus of the study had to be either one or
more of the following: (1) comparison with a normative
population, (2) studying the relation between treatment and
HRQoL, (3) studying the relation between socio-
demographic or clinical characteristics and HRQoL.
The search resulted in 270 hits. Based on titles and
abstracts, 24 articles met our selection criteria and were
included in this review (Fig. 1).
Quality assessment
Themethodologicalqualityoftheselectedstudieswasassessed
using a 12-item standardized checklist of predefined criteria
which was a modified version of an established criteria list for
systematic reviews (Table 1)[ 13, 14]. Each item of a study,
which met our criteria, was assigned one point. If an item that
did not meet our criteria was described insufficiently, or not at
all, then zero points were assigned. The highest possible score
was 12. Studies scoring ≥8 points were considered to be of
‘high quality’. Studies scoring <6 points or 6–8 points were
rated respectively as low and moderate quality.
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The following criteria were used to determine clinically
important differences. For the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30), a score greater than or
equal to a 10-point difference on subscales reflects a
clinical important difference [9, 15–18]. Concerning the
RAND Short Form-36 (SF-36), differences of ≥2 points for
role physical functioning; ≥3 points for physical function-
ing, social functioning, bodily pain, general health, vitality,
mental health and the component scales; ≥4 points for role
emotional functioning are considered clinically meaningful
[19, 20]. For the other questionnaires and some subscales,
Norman’s ‘rule of thumb’ was used whereby a ≈0.5 SD
difference indicates a threshold of discriminating change in
HRQoL scores of a chronic illness [21].
Results
Study characteristics
In total, 24 studies were included (14 HL [9, 15, 16, 22–
32]) and ten NHL [11, 17, 33–40]) all published between
February 1994 and November 2010. Only one study was
conducted outside the US and Europe [40]. The time since
diagnosis ranged between circa 2 months and 44 years. The
most frequently used questionnaires of HRQoL were the
EORTC QLQ-C30 (ten studies) [41] and the SF-36 (11
studies) [42]. Two studies used the Schedule for the
Evaluation of Individual Quality of Life–Direct Weighting
(SEIQoL-DW) [43], and three studies used the Functional
Assessment of Cancer Therapy-General (FACT-G) [44].
With respect to HL, two studies had a prospective
design, and 12 studies had a cross-sectional design. Of the
14 studies, ten cross-sectional studies compared HL
survivors and the general population, two prospective and
eight cross-sectional studies evaluated the relation with
treatment, and two prospective and nine cross-sectional
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Fig. 1 Flow diagram of papers
accepted and rejected during
selection procedure
Table 1 List of criteria for assessing the methodological quality of
studies on health-related quality of life among Hodgkin’s and non-
Hodgkin’s lymphoma
Positive if with respect to
Quality of life assessment
1. Avalidated (Health-Related) Quality of Life Questionnaire is used
(e.g. SF36, EORTC-C30)
Study population
2. A description of at least two socio-demographic variables is
included
3. A description of at least two clinical variables of the described
patient population (e.g. tumour stage at diagnosis) is present
4. Inclusion and/or exclusion criteria are described
5. Participation rates for patient groups are described and are more
than 60%
6. Information is given about the degree of selection of sample
(information is given about the ratio respondents vs. non-
respondents)
Study design
7. The study size consists of at least 50 participants (arbitrarily
chosen)
8. The data are prospectively gathered
9. The process of data collection is described (e.g. interview or self-
report)
Results
10. The results are compared between two groups or more (e.g.
healthy population, groups with different treatment or age) and/or
results are compared with at least two time points (e.g.,
longitudinally vs. post-treatment)
11. Mean, median, standard deviations or percentages are reported for
the most important outcome measures
12. Statistical proof for the findings is reported
Ann Hematol (2011) 90:993–1004 995studies reported about potential differences in socio-
demographic and clinical characteristics (Table 2). With
respect to NHL, four studies had a prospective design and
six studies had a cross-sectional design. Of the ten studies,
two prospective and three cross-sectional studies compared
NHL survivors and the general population, three prospec-
tive and two cross-sectional studies evaluated the relation
with treatment, and nine studies reported about the potential
differences in socio-demographic and clinical character-
istics (Table 3).
The evaluation of the methodological quality of the
studies by the reviewers (SO, FM, LP) yielded the
following results. On items 1, 5, 7, 8, 9, 11 and 12 there
was disagreement once, and on items 2, 3 and 10 there was
no disagreement. On items 4 and 6 (see Table 1), there was
disagreement a couple of times, mostly due to differences in
interpretation of the text. These were solved through
discussion in a consensus meeting. The methodological
quality of all included studies ranged from 8 to 12 points
and was thus considered to be of high quality. General
shortcomings concerned mainly the lack of information on
non-respondents (n=11) and the lack of a prospective
design (n=16).
Hodgkin’s lymphoma
HRQoL domains: HL survivors vs. normative samples
Four cross-sectional studies found clinically important
lower physical functioning scores for survivors compared
to a normative population [9, 26, 30, 32]. No clinically
important differences were found in six studies [15, 22, 24,
27, 28, 31].
Five studies found that HL survivors had clinically
important lower scores on social functioning compared to
normative samples [9, 15, 22, 24, 26]. Three studies found
no clinically important differences on social functioning
[27, 28, 30].
One study among 98 survivors that survived more than
8 years found that HL survivors had clinically important
lower scores on emotional functioning compared to the
normative sample [22] while seven studies found no
clinically important differences [9, 15, 24, 26–28, 30].
Five studies found that HL survivors had clinically
important lower scoresonrolephysicalfunctioningcompared
to the normative sample [9, 22, 26, 27, 30]. Three studies
found no clinically important differences [15, 24, 28].
No clinically important differences were found between
HL survivors and normative samples with respect to Global
health state (six studies) [15, 22, 24, 27, 28, 31].
Three cross-sectional studies found that HL survivors
had clinically important lower scores on general health
compared to the normative sample [9, 26, 30]. Two cross-
sectional studies found no clinically important differences
on general health [28, 31].
No clinically important differences were found between
HL survivors and normative samples regarding mental
health scores (four studies) [9, 26, 28, 30].
Symptoms: HL survivors vs. normative samples
Clinically important worse scores of HL survivors were
reported on several symptoms; cognitive problems [15, 22,
27], financial difficulties [15, 22, 24], fatigue/vitality [9, 15,
22], dyspnea [22, 27] and insomnia [15, 22] were reported
most often. Diarrhoea [22] and pain [26] were reported by
one study each. Three studies found no clinically important
differences between HL survivors and normative samples
[9, 13, 30].
Treatment and HRQoL in HL survivors
One prospective study among 247 early stage HL survivors
[23] found clinically important lower scores on vitality
among patients treated with a combination of radiotherapy
and chemotherapy compared to patients treated with
radiotherapy alone, but only in the first year after treatment.
This effect was also found in a cross-sectional study among
126 HL survivors in Austria [25]. They reported that
patients treated with a combination of radiotherapy and
chemotherapy showed clinically important lower scores on
physical functioning and clinically important higher scores
on pain, fatigue and dyspnoea compared to patients who
were treated with radiotherapy or chemotherapy alone. Two
small cross-sectional studies also found clinical important
higher scores on dyspnoea. One found that 26 patients
treated with mantle field irradiation reported higher scores
compared with patients treated without (n=16) [29]. The
other study found that 37 patients treated with high dose
chemotherapy and stem cell transplantation reported higher
scores compared with patients treated with conventional
chemotherapy (n=61) [22]. Another prospective and four
cross-sectional studies found no effect of treatment on
HRQoL [9, 16, 24, 28, 32].
Socio-demographic and clinical characteristics in HL
survivors
Three cross-sectional and one prospective study observed
that older patients reported clinically important worse
outcomes [9, 16, 24, 27]. Six studies reported contradicting
differences in HRQoL according to gender [9, 15, 16, 24,
27, 29], three studies found clinically important worse
scores for women [9, 24, 27], one found only statistically
worse scores for women [16], one found worse scores for
men [29] and one found no differences [15]. Two cross-
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g
n
i
f
i
c
a
n
t
l
y
l
o
w
e
r
i
n
p
a
t
i
e
n
t
s
t
h
a
n
i
n
c
o
n
t
r
o
l
s
,
a
n
d
t
h
e
s
o
c
i
a
l
o
p
e
r
a
t
i
o
n
s
c
a
l
e
t
h
a
t
r
e
f
e
r
s
t
o
t
h
e
s
o
c
i
a
l
f
a
m
i
l
i
a
l
r
e
l
a
t
i
o
n
s
h
i
p
s
o
f
t
h
e
i
n
d
i
v
i
d
u
a
l
s
w
a
s
a
l
s
o
l
o
w
e
r
i
n
p
a
t
i
e
n
t
s
t
h
a
n
i
n
c
o
n
t
r
o
l
s
.
H
L
s
u
r
v
i
v
o
r
s
a
l
s
o
s
c
o
r
e
d
w
o
r
s
e
o
n
t
h
e
d
y
s
p
n
o
e
a
s
c
a
l
e
a
n
d
r
e
p
o
r
t
e
d
m
o
r
e
e
c
o
n
o
m
i
c
a
l
d
i
f
f
i
c
u
l
t
i
e
s
.
N
o
d
i
f
f
e
r
e
n
c
e
b
e
t
w
e
e
n
t
r
e
a
t
m
e
n
t
s
w
a
s
f
o
u
n
d
.
1
0
G
o
o
d
m
a
n
e
t
a
l
.
,
2
0
0
8
,
U
S
A
[
1
5
]
6
0
M
e
a
n
,
4
3
;
r
a
n
g
e
,
2
4
–
6
5
C
h
e
m
o
t
h
e
r
a
p
y
a
n
d
a
u
t
o
l
o
g
o
u
s
s
t
e
m
c
e
l
l
r
e
s
c
u
e
M
e
a
n
=
1
2
y
e
a
r
s
(
6
–
1
8
)
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
E
O
R
T
C
Q
L
Q
-
C
3
0
Y
e
s
,
c
o
m
p
a
r
i
s
o
n
w
i
t
h
t
h
e
g
e
n
e
r
a
l
p
o
p
u
l
a
t
i
o
n
N
o
Y
e
s
G
l
o
b
a
l
H
R
Q
o
L
o
f
H
L
s
u
r
v
i
v
o
r
s
w
a
s
c
o
m
p
a
r
a
b
l
e
w
i
t
h
t
h
e
g
e
n
e
r
a
l
p
o
p
u
l
a
t
i
o
n
,
b
u
t
f
o
r
s
p
e
c
i
f
i
c
d
o
m
a
i
n
s
,
r
e
s
p
o
n
d
e
n
t
s
’
s
c
o
r
e
s
i
n
d
i
c
a
t
e
d
r
e
d
u
c
e
d
f
u
n
c
t
i
o
n
i
n
g
a
n
d
w
o
r
s
e
s
y
m
p
t
o
m
s
:
c
o
g
n
i
t
i
v
e
a
n
d
s
o
c
i
a
l
f
u
n
c
t
i
o
n
i
n
g
,
f
a
t
i
g
u
e
,
i
n
s
o
m
n
i
a
a
n
d
f
i
n
a
n
c
i
a
l
p
r
o
b
l
e
m
s
.
8
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r
e
i
l
e
t
a
l
.
,
1
9
9
9
,
A
u
s
t
r
i
a
[
2
5
]
1
2
6
M
e
a
n
,
3
7
;
S
D
,
1
6
.
3
;
r
a
n
g
e
,
6
–
8
9
C
h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
n
=
1
0
.
5
y
e
a
r
s
(
0
.
9
–
3
4
)
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
E
O
R
T
C
Q
L
Q
-
C
3
0
N
o
Y
e
s
Y
e
s
T
h
e
s
c
o
r
e
s
i
n
d
i
c
a
t
e
h
i
g
h
s
c
o
r
e
s
o
n
H
R
Q
o
L
p
a
r
a
m
e
t
e
r
s
i
n
a
l
l
s
u
b
s
c
a
l
e
s
i
n
H
L
s
u
r
v
i
v
o
r
s
a
f
t
e
r
a
m
e
a
n
p
e
r
i
o
d
o
f
9
.
1
y
e
a
r
s
f
r
o
m
t
h
e
t
i
m
e
o
f
t
h
e
i
n
i
t
i
a
l
d
i
a
g
n
o
s
i
s
.
H
L
s
u
r
v
i
v
o
r
s
t
r
e
a
t
e
d
w
i
t
h
c
o
m
b
i
n
e
d
m
o
d
a
l
i
t
y
t
h
e
r
a
p
y
s
h
o
w
e
d
w
o
r
s
e
p
h
y
s
i
c
a
l
f
u
n
c
t
i
o
n
i
n
g
a
n
d
m
o
r
e
f
a
t
i
g
u
e
,
p
a
i
n
a
n
d
d
y
s
p
n
o
e
a
.
1
0
H
e
u
t
t
e
e
t
a
l
.
,
2
0
0
9
,
F
r
a
n
c
e
[
1
6
]
9
3
5
M
e
a
n
:
n
o
t
r
e
p
o
r
t
e
d
;
r
a
n
g
e
:
,
1
5
–
7
0
C
h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
n
=
9
0
m
o
n
t
h
s
(
5
2
–
1
1
8
)
P
r
o
s
p
e
c
t
i
v
e
,
l
o
n
g
i
t
u
d
i
n
a
l
E
O
R
T
C
Q
L
Q
-
C
3
0
N
o
Y
e
s
Y
e
s
H
L
s
u
r
v
i
v
o
r
s
s
h
o
w
e
d
a
s
i
g
n
i
f
i
c
a
n
t
i
m
p
r
o
v
e
m
e
n
t
i
n
m
o
s
t
H
R
Q
o
L
d
o
m
a
i
n
s
w
i
t
h
i
n
1
8
m
o
n
t
h
s
o
f
t
h
e
e
n
d
o
f
t
r
e
a
t
m
e
n
t
,
e
x
c
e
p
t
f
o
r
c
o
g
n
i
t
i
v
e
f
u
n
c
t
i
o
n
i
n
g
.
B
y
c
o
n
t
r
a
s
t
,
v
e
r
y
f
e
w
p
a
t
i
e
n
t
s
s
h
o
w
e
d
H
R
Q
o
L
i
m
p
a
i
r
m
e
n
t
.
H
L
s
u
r
v
i
v
o
r
s
c
o
r
e
s
a
r
e
s
i
m
i
l
a
r
t
o
t
h
e
g
e
n
e
r
a
l
p
o
p
u
l
a
t
i
o
n
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t
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h
e
d
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o
r
a
g
e
a
n
d
s
e
x
.
1
2
H
j
e
r
m
s
t
a
d
e
t
a
l
.
,
4
7
5
M
e
a
n
:
4
6
S
D
:
1
1
.
6
C
h
e
m
o
t
h
e
r
a
p
y
,
1
9
5
m
o
n
t
h
s
(
5
3
–
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
S
F
-
3
6
Y
e
s
,
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o
m
p
a
r
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o
n
N
o
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o
O
v
e
r
a
l
l
,
H
L
s
u
r
v
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v
o
r
s
r
e
p
o
r
t
e
d
l
o
w
e
r
1
1
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a
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e
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c
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n
t
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n
u
e
d
)
S
t
u
d
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,
y
e
a
r
,
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o
u
n
t
r
y
N
u
m
b
e
r
M
e
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n
a
g
e
,
S
D
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r
r
a
n
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e
T
r
e
a
t
m
e
n
t
T
i
m
e
s
i
n
c
e
d
i
a
g
n
o
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s
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e
s
i
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n
Q
u
a
l
i
t
y
o
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l
i
f
e
i
n
s
t
r
u
m
e
n
t
s
C
o
m
p
a
r
i
s
o
n
n
o
r
m
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o
p
u
l
a
t
i
o
n
E
v
a
l
u
a
t
i
o
n
t
r
e
a
t
m
e
n
t
e
f
f
e
c
t
E
v
a
l
u
a
t
i
o
n
o
t
h
e
r
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
G
e
n
e
r
a
l
c
o
n
c
l
u
s
i
o
n
s
M
e
t
h
o
d
o
l
o
g
i
c
a
l
q
u
a
l
i
t
y
s
c
o
r
e
(
m
a
x
i
m
u
m
s
c
o
r
e
=
1
2
)
2
0
0
6
,
N
o
r
w
a
y
[
2
6
]
R
a
n
g
e
:
2
1
–
7
4
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
4
3
1
)
w
i
t
h
n
a
t
i
o
n
a
l
l
y
r
e
p
r
e
s
e
n
t
a
t
i
v
e
g
e
n
e
r
a
l
p
r
a
c
t
i
t
i
o
n
e
r
d
a
t
a
H
R
Q
o
L
t
h
a
n
t
h
e
g
e
n
e
r
a
l
p
o
p
u
l
a
t
i
o
n
.
S
u
r
v
i
v
o
r
s
s
c
o
r
e
d
s
i
g
n
i
f
i
c
a
n
t
l
y
w
o
r
s
e
o
n
b
o
d
i
l
y
p
a
i
n
,
g
e
n
e
r
a
l
h
e
a
l
t
h
,
(
r
o
l
e
)
p
h
y
s
i
c
a
l
f
u
n
c
t
i
o
n
i
n
g
a
n
d
s
o
c
i
a
l
f
u
n
c
t
i
o
n
i
n
g
.
J
o
l
y
e
t
a
l
.
,
1
9
9
6
,
F
r
a
n
c
e
[
2
7
]
9
3
M
e
a
n
,
4
2
;
r
a
n
g
e
,
2
3
–
8
5
C
h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
n
=
1
0
y
e
a
r
s
(
r
a
n
g
e
,
4
–
1
7
)
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
E
O
R
T
C
Q
L
Q
-
C
3
0
Y
e
s
,
c
a
s
e
c
o
n
t
r
o
l
N
o
Y
e
s
C
o
m
p
a
r
e
d
t
o
c
o
n
t
r
o
l
s
,
H
L
p
a
t
i
e
n
t
s
r
e
p
o
r
t
e
d
m
o
r
e
p
h
y
s
i
c
a
l
,
r
o
l
e
a
n
d
c
o
g
n
i
t
i
v
e
f
u
n
c
t
i
o
n
i
n
g
i
m
p
a
i
r
m
e
n
t
s
,
a
s
w
e
l
l
a
s
d
y
s
p
n
o
e
a
a
n
d
c
h
r
o
n
i
c
f
a
t
i
g
u
e
,
w
h
i
l
e
n
o
s
t
a
t
i
s
t
i
c
a
l
d
i
f
f
e
r
e
n
c
e
w
a
s
f
o
u
n
d
i
n
g
l
o
b
a
l
h
e
a
l
t
h
s
t
a
t
u
s
.
1
0
M
o
l
s
e
t
a
l
.
,
2
0
0
6
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
[
2
8
]
1
3
2
N
o
t
r
e
p
o
r
t
e
d
C
h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
n
=
5
–
1
5
y
e
a
r
s
P
o
p
u
l
a
t
i
o
n
-
b
a
s
e
d
,
c
r
o
s
s
-
s
e
c
t
i
o
n
a
l
S
F
-
3
6
Y
e
s
,
c
o
m
p
a
r
i
s
o
n
w
i
t
h
a
n
a
g
e
d
m
a
t
c
h
e
d
n
o
r
m
a
t
i
v
e
s
a
m
p
l
e
Y
e
s
Y
e
s
H
R
Q
o
L
a
m
o
n
g
H
L
s
u
r
v
i
v
o
r
s
i
s
l
o
w
e
r
c
o
m
p
a
r
e
d
t
o
a
n
a
g
e
-
m
a
t
c
h
e
d
n
o
r
m
a
t
i
v
e
s
a
m
p
l
e
.
S
u
r
v
i
v
o
r
s
s
c
o
r
e
d
w
o
r
s
e
o
n
g
e
n
e
r
a
l
h
e
a
l
t
h
,
v
i
t
a
l
i
t
y
,
s
o
c
i
a
l
f
u
n
c
t
i
o
n
-
i
n
g
.
N
o
d
i
f
f
e
r
e
n
c
e
s
b
e
t
w
e
e
n
t
r
e
a
t
m
e
n
t
s
w
e
r
e
r
e
p
o
r
t
e
d
.
1
1
N
o
r
u
m
e
t
a
l
.
,
1
9
9
6
,
N
o
r
w
a
y
[
2
9
]
4
2
N
o
t
r
e
p
o
r
t
e
d
C
h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
1
6
–
2
0
m
o
n
t
h
s
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
E
O
R
T
C
Q
L
Q
-
C
3
0
N
o
Y
e
s
Y
e
s
H
L
s
u
r
v
i
v
o
r
s
r
e
p
o
r
t
e
d
a
l
o
w
f
r
e
q
u
e
n
c
y
o
f
s
y
m
p
t
o
m
s
a
n
d
a
h
i
g
h
l
e
v
e
l
o
f
f
u
n
c
t
i
o
n
i
n
g
.
S
u
r
v
i
v
o
r
s
t
r
e
a
t
e
d
w
i
t
h
m
a
n
t
l
e
f
i
e
l
d
i
r
r
a
d
i
a
t
i
o
n
a
n
d
m
a
l
e
s
s
e
e
m
t
o
b
e
a
t
h
i
g
h
e
r
r
i
s
k
.
8
V
a
n
T
u
l
d
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r
e
t
a
l
.
,
1
9
9
4
,
T
h
e
N
e
t
h
e
r
l
a
n
d
s
[
3
0
]
8
1
M
e
a
n
,
4
7
;
S
D
,
1
1
;
r
a
n
g
e
,
2
5
–
7
7
R
a
d
i
o
t
h
e
r
a
p
y
v
s
.
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
n
=
1
4
y
e
a
r
s
(
1
0
–
1
8
)
C
r
o
s
s
-
s
e
c
t
i
o
n
a
l
S
F
-
3
6
Y
e
s
,
c
o
m
p
a
r
i
s
o
n
w
i
t
h
h
o
s
p
i
t
a
l
v
i
s
i
t
o
r
s
m
a
t
c
h
e
d
f
o
r
a
g
e
a
n
d
s
e
x
N
o
N
o
S
e
l
f
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r
e
p
o
r
t
e
d
H
R
Q
o
L
o
f
H
L
s
u
r
v
i
v
o
r
s
i
s
s
t
i
l
l
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f
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e
c
t
e
d
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o
1
8
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e
a
r
s
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f
t
e
r
t
r
e
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t
m
e
n
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.
I
n
p
a
r
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c
u
l
a
r
,
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h
y
s
i
c
a
l
a
n
d
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o
l
e
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u
n
c
t
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n
i
n
g
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e
x
u
a
l
i
t
y
a
n
d
o
v
e
r
a
l
l
h
e
a
l
t
h
p
e
r
c
e
p
t
i
o
n
s
a
p
p
e
a
r
t
o
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p
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.
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r
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.
,
2
0
0
3
,
S
w
e
d
e
n
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1
]
1
2
1
M
e
a
n
,
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1
1
.
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h
e
m
o
t
h
e
r
a
p
y
,
r
a
d
i
o
t
h
e
r
a
p
y
o
r
c
o
m
b
i
n
e
d
t
h
e
r
a
p
y
M
e
a
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=
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y
e
a
r
s
C
r
o
s
s
-
s
e
c
t
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o
n
a
l
S
E
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o
L
-
D
W
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m
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r
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o
n
w
i
t
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n
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p
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c
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c
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b
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n
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n
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n
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i
e
s
a
r
o
u
n
d
d
i
s
e
a
s
e
,
f
a
t
i
g
u
e
a
n
d
l
o
s
s
o
f
e
n
e
r
g
y
a
n
d
l
a
t
e
e
f
f
e
c
t
s
o
n
s
k
i
n
a
n
d
m
u
c
o
u
s
m
e
m
b
r
a
n
e
w
e
r
e
t
h
e
m
o
s
t
c
o
m
m
o
n
l
y
r
e
p
o
r
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p
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g
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r
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d
e
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h
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b
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1
Ann Hematol (2011) 90:993–1004 999sectional studies reported that more advanced disease stage
or recurrences were associated with reduced HRQoL;
however, no information about clinically important differ-
ences could be obtained [15, 32]. One study found
remarkably that patients with stage IB–IIB scored signifi-
cantly and clinically important lower on physical function-
ing and physical role limitations compared to patients with
stage IA–IIA, IIIA–IV A and IIIB–IVB [9].
The impact of length of survival on HRQoL was
reported in a cross-sectional study, showing that patients
who had survived 10–15 years after diagnosis reported
clinically important higher HRQoL scores than patients
who had survived 5–9 years [28].
Non-Hodgkin’s lymphoma
HRQoL domains: NHL survivors vs. normative samples
In a prospective study among 95 Norwegians [17], patients
showed clinically important lower scores on physical
functioning up until 5 months after start of therapy
compared to the normative sample. However, 8 months
after end of treatment, the difference was no longer
clinically relevant. A Dutch cross-sectional study among
294 survivors [11] and an American cross-sectional study
of 319 survivors found no clinically important lower scores
for survivors compared to the normative sample on physical
functioning [33]. A cross-sectional study of 761 survivors
[39] showed clinically important lower scores on the
physical component scale. Another prospective study found
statistically lower scores 2 years post-diagnosis; however,
no information about clinically important differences could
be obtained [37].
A prospective study [17] exhibited clinically important
lower scores on social functioning up until 6 months after
start of therapy compared to the reference population.
However, 8 months after end of treatment, the difference
was no longer clinically relevant. Two years post-diagnosis,
another prospective study found statistically lower scores;
however, no information about clinically important differ-
ences could be obtained [37]. A cross-sectional study found
no clinically important differences with respect to social
functioning [11].
A prospective study [17] showed clinically important
lower scores on role physical function compared to the
general population, and these scores remained clinically
important lower until the end of the study (8 months).
Another prospective study found statistically lower scores
2 years post-diagnosis; however, no information about
clinically important differences could be obtained [37].
However, a cross-sectional study found no clinically
important differences regarding role physical function
[11].
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1000 Ann Hematol (2011) 90:993–1004Two prospective and a cross-sectional study did not find
statistically or clinically important differences with respect
to emotional functioning between NHL survivors and the
normative populations [11, 17, 37].
A prospective study [17] exhibited clinically important
lower scores on global health state up until 5 months after
start of therapy compared to the reference population.
However, 8 months after the end of treatment, the
difference was no longer clinically relevant.
In addition, a cross-sectional study among 294 survivors
showed clinically important lower scores on general health
[11]. A prospective study found statistically lower scores
2 years post-diagnosis; however, no information about
clinically important differences could be obtained [37].
Three cross-sectional studies did not find clinically impor-
tant differences between NHL survivors and the reference
population on mental health [11, 33, 39].
Symptoms: NHL survivors vs. normative samples
A prospective study [17] showed clinically important lower
scores on appetite loss, constipation, fatigue and dyspnoea
up until respectively 3 months for the first two symptoms
and 5 months for the last two symptoms after start of
therapy compared to the reference population. However,
8 months after the end of treatment the difference was no
longer clinically relevant. Furthermore, they found that
9 months after the end of treatment until the end of the
study, survivors had clinically more financial difficulties
than the normative sample. A cross-sectional and prospec-
tive study found statistically lower scores for survivors on
vitality [28, 37], clinically important differences were only
found by the cross-sectional study [28].
Treatment and HRQoL in NHL survivors
Three prospective studies showed no significantly different
outcomes regarding HRQoL between patients treated with
different chemotherapy regimens [17, 34, 35]. Two cross-
sectional studies found that, compared to patients who did
not receive chemotherapy, patients who did receive chemo-
therapy experienced clinically important worse overall
health functioning [36] and social well-being [11].
Socio-demographic and clinical characteristics in NHL
survivors
A prospective study did not find a relation between age and
HRQoL outcome [17]. One cross-sectional study [11] found
that older patients scored significantly lower on physical
functioning than younger patients; however, no information
about clinically important differences could be obtained.
Another cross-sectional study found clinical meaningful
worse physical HRQoL scores for survivors who were older
at study enrolment [38].
Two prospective studies [34, 35] found that survivors
with progressive disease had clinically meaningful lower
HRQoL than patients who were free of disease. Another
prospective study found no relation between disease stage
and HRQoL [17]. Two cross-sectional studies found
statistically lower HRQoL scores for survivors with active
(relapsed) disease compared to disease-free survivors [36,
39]; clinically important differences were found in one of
them [36].
The impact of length of survival was reported in a cross-
sectional study [11] showing that patients who had survived
10–15 years after diagnosis reported clinically important
higher HRQoL scores than patients who had survived 5–
9 years, but this was not observed by another study [39]
that compared short-term (2–5 years after diagnosis) and
long-term (≥5 years after diagnosis) survivors.
Two prospective studies [34, 35] investigated HRQoL in
elderly patients in relation to the age-adjusted International
Prognostic Index which comprises three factors (perfor-
mance status, lactate dehydrogenase and stage) [45]. These
studies found that patients with a low age-adjusted
International Prognostic Index had a clinically meaningful
better HRQoL than patients with a high age-adjusted
International Prognostic Index. One prospective study
found no relation between International Prognostic Index
and HRQoL [17].
Two cross-sectional studies found that survivors meeting
public health exercise guidelines reported a clinically
meaningfully better mental and physical health [33, 40]
than survivors not meeting these guidelines. Even more
important, one of these studies [33] found that there was a
significant dose–response pattern in which more exercise
resulted in better mental and physical health.
Discussion
This systematic review summarized and evaluated the
results of studies focusing on the HRQoL of HL and
NHL survivors. It is a remarkable fact that the majority of
these studies concerned HL and not NHL, certainly in view
of the number of patients being treated (8,500 vs. 65,000)
or the number of survivors (165,000 vs. 440,000) [5].
Another point is that the first included study on HRQoL in
HL was published in 1994, whereas all included studies on
HRQoL in NHL were published after 2004.
The quality scores of the included HL studies ranged
from eight to 12 points, which indicate a high methodo-
logical quality. The shortcomings of these studies were
mainly the lack of a prospective design and lack of
information on non-respondents. The HRQoL domains that
Ann Hematol (2011) 90:993–1004 1001were affected the most in these patients and represent
clinically important differences to patients were (role)
physical, social and cognitive functioning, general health,
fatigue and financial problems, and fewer dyspnoea and
insomnia. Clinically important differences in emotional
functioning, diarrhoea and pain were reported once. No
clinically important differences were found in the included
studies for physical functioning and mental health. Based
on the studies included in this review, HL survivors who
received a combination of chemotherapy and radiotherapy
[23, 25] had worse scores on HRQoL domains. A clinically
important higher score on dyspnoea was found by all
therapies, and this suggests that treatment in general results
in problems [29]. However, most of the studies found no
differences. In addition, HL survivors with older age and
females reported worse outcomes. As expected, patients
with a longer survival time reported better outcomes
compared to those more recently diagnosed.
With respect to the included NHL studies, it was not
possibletodividetheresultssectioninaggressiveandindolent
lymphomas due to lack of information within most available
studies.ThequalityscoresofNHLstudiesrangedfromnineto
12 points, which indicate a high methodology quality. The
shortcomings were mainly a lack of a prospective design. The
HRQoL domains that were affected the most in NHL
survivors and represent clinically important differences to
patients were physical functioning, appetite loss, vitality and
financial problems. Clinically important differences in social
functioning, role physical functioning and global health were
mentioned once up until 5 months after treatment but waned
overtime.Whencomparingdifferentchemotherapyregimens,
no differences were reported. Nevertheless, having had
chemotherapy was associated with clinically important lower
scoresonsocialwell-being[11] and overall health functioning
[36] as reported by two cross-sectional studies in (long-term)
cancer survivors. Interestingly, the effect of exercise was
studied in NHL patients, whereas this has not been
investigated in HL survivors. NHL survivors that met public
health exercise guidelines reported a clinically important
better HRQoL than survivors that did not meet exercise
guidelines [33, 40], and even more important, more exercise
resulted in a better mental and physical health [33]. Most
studies showed worse HRQoL for survivors with aggressive
disease or partial response, no response or progressive
disease [34–36, 39], and those with a high age-adjusted
Prognostic Index [34, 35], which is well understandable.
The criterion of clinically important differences is very
important to specify those domains of HRQoL that are
affected in survivors. Most of the included studies based their
conclusions only on statistical significance. Sometimes differ-
ences between survivors and comparative groups were
statistically significant, but not clinically important for
patients. Therefore, researchers should always use a criterion
for the interpretation of clinical relevance instead of only
evaluating the statistical significance to really attribute to the
care of patients. Of the 17 included studies that compared
HRQoL between survivors and a normative population, only
seven [9, 15–17, 28, 32, 39] studies used a criterion to
determine clinically relevant differences.
When comparing different studies, certainly in the field of
HRQoL, there are many limitations. Seventeen of 22 included
papers had a cross-sectional design[9, 11, 15, 24–33, 39, 40].
A limitation of this methodology is that it is not possible to
draw causal relationships. In addition, these studies may have
survivorship bias because patients that do relatively worse
will not participate as they are too ill or dead. A prospective
design study provides better relevant answers about causality,
for example the temporal direction between treatment and
HRQoL, but only five studies had this design. Also, the lack
of information in some studies on non-respondents or
possible bias makes it more difficult to determine the
trustworthiness of a study. Future studies should therefore
always try to collect data on non-respondents or discuss the
possible risk of bias. Although there are inherent relation-
ships between HRQoL dimensions, we discussed the
dimensions separately to identify which specific dimensions
are most affected. This does not mean that the unmentioned
dimensions could not be affected. However, the underlying
mechanisms between the relations in HRQoL dimensions
and symptoms are understudied and not yet clear. Therefore,
studies focusing on symptom clustering are needed.
The different HRQoL questionnaires used, predominantly
the EORTC QLQ-C30 (disease-specific questionnaire) and
the SF-36 (generic questionnaire) made it difficult to compare
results, as the various scales do not exactly measure the same
HRQoL dimensions. The questionnaires in the included
studies were almost all generic or disease specific. Generic
questionnaires are designed to measure health in general, and
are therefore appropriate for a wide range of patient groups
and also the general population, but are less sensitive todetect
certain aspects of disease and treatment that are relevant to a
specific patient group. The EORTC QLQ-C30 is a disease
specific questionnaire, but consists of such questions that this
questionnaire isalsoapplicabletothe general population[46].
In addition to these generic and disease-specific question-
naires, lymphoma-specific questionnaires should be used to
detect, with more sensibility, side effects and symptoms
particularly relevant to HL and NHL survivors. However,
cancer-specific questionnaires are relatively new and under-
developed and therefore used infrequently. Only two studies
[36, 39] used a lymphoma-specific questionnaire, the FACT-
lymphoma, which was developed in 2004 [44].
The American Cancer Society defines ‘long-term survi-
vors’ as every person who is still alive 5 years after
diagnosis [47]. Six studies, five HL [15, 28, 30–32] and one
NHL [11], focused on patients who had survived more than
1002 Ann Hematol (2011) 90:993–10045 years. Only one recent study focused on the longitudinal
HRQoL of HL survivors [16]. Especially these kinds of
studies are important in view of the growing number of
survivors to identify as soon as possible negative long-term
effects, certainly when taken into consideration the imple-
mentation of new treatments.
If we compare the results of the 11 cross-sectional and two
prospective studies among the HL survivors, some cross-
sectional studies are consistent with the prospective studies on
points as comparison with the norm population, relation with
received treatment, and socio-demographic and clinical differ-
ences. However, if we compare the two prospective HLstudies,
one [23] did find a relation with treatment while the other [16]
did not. With respect to NHL studies, again some of the cross-
sectional studies (four) are consistent with the prospective
ones. However, if we compare the three prospective studies,
only consistent results concerning the absence of the relation
with treatment on HRQoL were found [17, 34, 35].
In conclusion, the reviewed literature about the HRQoL of
HL and NHL survivors reflects that several domains, even in
long-term survivors, are affected. Overall, HL survivors
experience the most problems in (role) physical, social and
cognitive functioning, general health, fatigue and financial
problems. In addition, HL survivors with older age and female
sex reported worse outcomes. NHL survivors experience the
most problems in physical functioning, appetite loss, vitality
and financial problems. However, these results are less clear as
only a limited number of studies are performed among NHL
survivors. Furthermore, importantly the HRQoL in NHL
survivors not meeting public exercise guidelines is low, but
can be improved with more exercise. More research on the
longitudinal comparison between HL and NHL survivors and
healthy controls should be performed. Lymphoma-specific
questionnaires should be further developed to better understand
in detail the side effects of treatment on HLand NHL survivors.
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